HealthEquity (HQY): Assessing Valuation in Light of Strong Earnings Growth and Upbeat Outlook

HealthEquity (HQY) just delivered its latest quarterly earnings report, and it’s the kind of update that grabs investors’ attention. The company posted strong year-over-year growth in both revenue and net income, while management set the tone for the rest of the year with upbeat earnings guidance. For anyone wondering whether the recent move signals something more, these numbers paint a clear picture of a business gaining traction and confidence at the top.

This surge of positive news arrives after what has been an eventful year for HealthEquity. The stock has climbed nearly 20% over the past year, though it has faced some volatility recently, dipping around 5% year to date and 15% over the past three months. That said, its multi-year track record is noteworthy, with notable three-year and five-year total returns. The company has also just completed another significant round of share buybacks, adding momentum to what was already a growth story.

With recent earnings running ahead of last year and the updated outlook hinting at more to come, is the market underestimating HealthEquity’s growth prospects, or has all of this been reflected in today’s share price?

Most Popular Narrative: 25.1% Undervalued

The prevailing narrative values HealthEquity at a significant discount based on future earnings and margin expansion expectations. This suggests the shares could offer considerable upside.

The recent regulatory expansion, allowing direct primary care, pre-deductible telehealth, and millions of new ACA bronze/catastrophic plan members to qualify for HSAs, creates the largest addressable market increase in two decades. This is poised to accelerate new account openings and AUM growth, meaningfully boosting future revenue. HealthEquity is leveraging digital transformation through its secure, AI-powered mobile app and automation initiatives. These efforts are enhancing member experience and engagement while driving operating leverage and reducing service costs, supporting higher net margins and improved earnings over time.

Could HealthEquity's valuation be hiding its real potential? The bold case is fueled by projected margin expansion, rapid earnings growth, and a premium future multiple. Which crucial assumptions do analysts believe justify such a high price target? The facts behind this story might just surprise you.

Result: Fair Value of $122.21 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent healthcare inflation or a weak labor market could dampen HealthEquity’s account growth and profitability. This may challenge the current growth outlook.

Find out about the key risks to this HealthEquity narrative.

Another View: What Do Valuation Ratios Say?

While some see upside from projected growth, the market’s favored valuation ratio tells a different story. This approach judges HealthEquity as pricier than the broader healthcare group. Could market optimism be running ahead of reality?

See what the numbers say about this price — find out in our valuation breakdown.

Stay updated when valuation signals shift by adding HealthEquity to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own HealthEquity Narrative

If you have your own take on HealthEquity, or want to see where the numbers lead, you can build your narrative in just a few minutes. Do it your way.

A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Don’t limit your sights to just one winner. Tap into these unique opportunities on Simply Wall Street, and you could uncover your next standout investment. Missing out here could leave you a step behind other smart investors.

• Boost your income stream by targeting steady payouts with dividend stocks with yields > 3%, which delivers yields above 3% from reliable companies.
• Ride the power of disruption and innovation by checking out AI penny stocks, featuring businesses making headlines at the cutting edge of artificial intelligence.
• Catch undervalued gems with undervalued stocks based on cash flows, designed to spotlight quality stocks trading below their cash flow fair values.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com